Preoperative systemic inflammatory markers (SII, PLR, MRR) as potential indicators of axillary lymph node metastasis in early-stage breast cancer Authors: Haofeng Wang, Beimin Gao, Haiyan Zhao, Jing Cui, Jinling Yu Published: 2026 ABSTRACT BackgroundAxillary lymph node metastasis (ALNM) in a pivotal prognostic indicator in breast cancer. Systemic Immune-Inflammation Index (SII), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Red blood cell Ratio (MRR), have emerged as potential predictive markers for ALNM given their ability to reflect host inflammatory and immune responses within the tumor microenvironment.MethodsWe retrospectively analyzed 293 data of patients with T1-T2 stage breast cancer treated between 2019 and 2024. Preoperative peripheral blood samples were collected to calculate SII, PLR, and MRR. Axillary lymph node status was determined through postoperative pathological examination. Receiver operating characteristic (ROC) curve analysis was used to establish optimal cut-off values for each index. Associations between inflammatory markers and ALNM were evaluated using univariate and multivariate logistic regression models, adjusting for age, tumor stage, molecular subtype, and other relevant clinicopathological factors.ResultsALNM was present in 121 patients (41.3%). Compared with patients without ALNM, those with ALNM had significantly higher PLR (p = 0.015), SII (p = 0.018), lower MRR values (p = 0.035). Multivariate analysis revealed that low PLR (vs. high; OR = 0.447), low SII (vs. high; OR = 0.323), and low MRR (vs. high; OR = 1.862) were independently associated with ALNM risk.ConclusionPreoperative SII, PLR, and MRR show modest discriminatory ability in early-stage breast cancer and may serve as supportive tools for risk stratification.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s12672-026-05520-0. Background Breast cancer is the most common malignancies and a leading causes of cancer-related mortality among women worldwide. At diagnosis, approximately 26% of patients exhibit metastatic involvement, frequently manifesting as regional lymph node metastasis or micrometastatic disease [1]. Although advances in surgery, radiotherapy, chemotherapy, and targeted therapies have substantially improved outcomes, axillary lymph node metastasis (ALNM) continues to represent a central prognostic factor and plays a decisive role in treatment selection [2]. Sentinel lymph node biopsy (SLNB) is the standard approach for axillary staging in early breast cancer. However, its false-negative rate, reported to be as high as 15%, raises concerns regarding potential understaging and subsequent undertreatment, and may necessitate secondary axillary lymph node dissection (ALND) in misdiagnosed cases [3]. Although ALND provides reliable regional control, it is associated with notable postoperative morbidity, including lymphedema, sensory impairment, and functional limitations, which may affect long-term quality of life [4]. These limitations underscore the importance of identifying accurate and minimally invasive methods to estimate ALNM risk before surgery. Systemic inflammation is increasingly recognized as a key component of cancer development and progression. Hematologic indices derived from routine blood tests, such as the Systemic Immune-Inflammation Index (SII), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Red Blood Cell Ratio (MRR), reflect the balance between pro-tumor inflammatory activity and antitumor immune responses [5–7]. Although these markers have been associated with survival outcomes in several malignancies, their value in predicting ALNM in breast cancer has not been fully clarified [8–10]. Although PLR and SII have been investigated in this context, the Monocyte-to-Red blood cell Ratio (MRR) has not been previously evaluated in relation to ALNM in early stage breast cancer, representing a novel aspect of our investigation. This study investigates the association between MRR and ALNM with exploratory analysis of potential biological mechanisms. By examining the relationship between systemic inflammatory status and nodal metastasis, we aim to provide additional evidence to support risk assessment and surgical decision-making in clinical practice. Methodology This retrospective study included breast cancer patients who underwent surgery for breast cancer at our institution between January 2019 and December 2024. Inclusion criteria were pathologically confirmed T1-T2 carcinoma. The exclusion criteria were evidence of active infection or systemic inflammatory disease (e.g., rheumatoid arthritis, lupus) within 4 weeks prior to surgery; history of hematological disorders; receipt of blood transfusion within 3 months prior to surgery; presence of locally advanced (≥ T3) or metastatic disease; and incomplete clinicopathological data. Patients with locally advanced tumors (≥ 5 cm) or evidence of distant metastases were excluded. Finally, 293 patients were included in the study. The sample size was considered sufficient and comparable to that in previous similar studies [11]. The patient enrollment process is illustrated in (Fig. 1). Fig. 1Study design and patient enrollment flowchart Study design and patient enrollment flowchart Clinical and pathological data were obtained from hospital records. Preoperative blood samples collected within 7 days before surgery were analyzed using a Sysmex XN-1000 hematology analyzer. Inflammatory indices were calculated as follows: PLR, platelet count/Lymphocyte count; MRR, monocyte count/red blood cell count; and SII, (platelet count × neutrophil count)/lymphocyte count. The optimal cut-off values for PLR, SII, and MRR were determined using receiver operating characteristic (ROC) curve analysis with Youden’s index (J = sensitivity + specificity − 1) to maximize the sum of sensitivity and specificity. To minimize confounding, all patients’ medical records were retrospectively reviewed to confirm the absence of the aforementioned exclusion criteria at the time of blood sampling. All statistical analyses were conducted using SPSS version 26.0. Categorical variables were analyzed with Chi-square test. Continuous variables were assessed using the Student’s t-test when normally distributed and the Mann–Whitney U test when distributional assumptions were not met. The associations between inflammatory indices and ALNM were evaluated using univariate and multivariate logistic regression models, with adjustment for age, clinical T stage, ER status, PR status, HER2 expression, Ki-67 index, and BMI. Multicollinearity among predictor variables was assessed using variance inflation factor (VIF) analysis. Variables with VIF > 10 were considered to have significant multicollinearity and were excluded from the final model.A two-sided p value < 0.05 was considered statistically significant. All figures and tables were prepared using standardized templates to ensure consistency in formatting and presentation. Result This study included 293 histologically confirmed breast cancer cases classified as T1–2 stage (Table 1), with a mean age of 55.89 years (range: 28–78). Among these patients, 216 (73.7%) were estrogen receptor (ER)-positive, 188 (64.2%) progesterone receptor (PR)-positive, 114 (38.9%) human epidermal growth factor receptor 2 (HER2)-positive, and 178 (60.8%) Ki-67-positive. Axillary lymph node metastasis (ALNM) was observed in 121 patients, yielding an incidence rate of 41.3%. Table 1Clinicopathological characteristics of 293 patientsParametersNumber of patients (n = 293) (%)Age, years, mean ± SD, range55.89 ± 10.62 (28–78)Platelet/lymphocyte ratio, mean ± SD, range158.6 ± 56.6 (44.4-423.9)Systemic immune-inflammation index, mean ± SD, range613.1 ± 326.6 (91.9-2528.2)Monocyte/red blood cell ratio, mean ± SD, range8.7 ± 2.5 (3.54–10.10)Tumor size, mm, mean ± SD,2.06 ± 0.95 (0.2-5.0)Clinical T stage T1169 (57.7%) T2124 (42.3%)Estrogen receptor Negative77 (26.3%) Positive216 (73.7%)Progesterone receptor Negative105 (35.8%) Positive188 (64.2%)HER2 Negative178 (60.8%) Positive115 (39.2%)Ki67 ≤20%113 (38.6%) >20%180 (61.4%)BMI <24158 (53.9%) ≥ 24135 (46.1%)N stage status N0172 (58.7%) N1121 (41.3%)USG, lymph node status No212 (72.4%) Yes81 (27.6%)Stage Stage 1113 (38.6%) Stage 2180 (61.4%)HER2: human epidermal growth factor receptor 2; BMI: body mass index Table 1Clinicopathological characteristics of 293 patientsParametersNumber of patients (n = 293) (%)Age, years, mean ± SD, range55.89 ± 10.62 (28–78)Platelet/lymphocyte ratio, mean ± SD, range158.6 ± 56.6 (44.4-423.9)Systemic immune-inflammation index, mean ± SD, range613.1 ± 326.6 (91.9-2528.2)Monocyte/red blood cell ratio, mean ± SD, range8.7 ± 2.5 (3.54–10.10)Tumor size, mm, mean ± SD,2.06 ± 0.95 (0.2-5.0)Clinical T stage T1169 (57.7%) T2124 (42.3%)Estrogen receptor Negative77 (26.3%) Positive216 (73.7%)Progesterone receptor Negative105 (35.8%) Positive188 (64.2%)HER2 Negative178 (60.8%) Positive115 (39.2%)Ki67 ≤20%113 (38.6%) >20%180 (61.4%)BMI <24158 (53.9%) ≥ 24135 (46.1%)N stage status N0172 (58.7%) N1121 (41.3%)USG, lymph node status No212 (72.4%) Yes81 (27.6%)Stage Stage 1113 (38.6%) Stage 2180 (61.4%)HER2: human epidermal growth factor receptor 2; BMI: body mass index Clinicopathological characteristics of 293 patients HER2: human epidermal growth factor receptor 2; BMI: body mass index The preoperative mean platelet-to-lymphocyte ratio (PLR) was 158.6 (range: 44.4–423.9), mean monocyte-to-lymphocyte ratio (MRR) was 8.7 (range: 3.54–10.10), and the mean systemic immune-inflammation index (SII) was 613.1 (range: 91.9–2528.2). Based on the predefined cut-off values, patients were stratified into high-PLR (n = 140, 47.8%), high-MRR (n = 132, 41.3%), and high-SII (n = 166, 56.7%) groups. Associations between clinicopathological characteristics and ALNM are summarized in Table 2. Homogeneity and Mann–Whitney U tests revealed that PLR, MRR, and SII were significantly correlated with ALNM. Specifically, patients with ALNM had significantly higher PLR (mean: 160.72 vs. 152.95, p = 0.015), lower MRR (mean: 8.42 vs. 8.99, p = 0.035), and higher SII (mean: 646.46 vs. 589.65, p = 0.018) compared to those without ALNM. Table 2Association between lymph node metastasis and clinicopathological factorsVariablesLymph nodeNo metastasis(172 patients 58.7%)Metastasis121 patients 41.3%P valueAge, years, mean ± SD, range55.29 ± 10.42 (32–77)56.75 ± 10.87 (28–78)0.184Tumor size, mm, mean ± SD,1.879 ± 0.93 (0.2–5)2.305 ± 0.93 (0.6–5)<0.001Platelet/lymphocyte ratio, mean ± SD, range152.95 ± 59.71 (66.61–414.00)160.72 ± 55.91 (44.35-311.35)0.015systemic immune-inflammation index, mean ± SD, range589.65 ± 318.34 (147.95–2528.15)646.46 ± 306.26 (91.85–1979.98)0.018Monocyte /red blood cell ratio, mean ± SD, range8.99 ± 2.60 (4.32–15.67)8.42 ± 2.35 (3.63–15.10)0.035Clinical T stage0.001 T111356 T25965Estrogen receptor0.018 Negative5423 Positive11898Progesterone receptor0.039 Negative7035 Positive10286HER20.394 Negative10870 Positive6451Ki670.685 ≤20%6845 >20%10476BMI index0.137 <249959 ≥ 247362Platelet to lymphocyte ratio (PLR)0.004 Low10251 High7070Monocyte to red cell ratio (MRR)0.006 Low8378 High8943Systemic immune-inflammation index(SII)< 0.001 Low9136 High8185HER2: human epidermal growth factor receptor 2; BMI: body mass index; MRR: monocyte to red cells ratio; PLR: platelet to lymphocyte ratio Table 2Association between lymph node metastasis and clinicopathological factorsVariablesLymph nodeNo metastasis(172 patients 58.7%)Metastasis121 patients 41.3%P valueAge, years, mean ± SD, range55.29 ± 10.42 (32–77)56.75 ± 10.87 (28–78)0.184Tumor size, mm, mean ± SD,1.879 ± 0.93 (0.2–5)2.305 ± 0.93 (0.6–5)<0.001Platelet/lymphocyte ratio, mean ± SD, range152.95 ± 59.71 (66.61–414.00)160.72 ± 55.91 (44.35-311.35)0.015systemic immune-inflammation index, mean ± SD, range589.65 ± 318.34 (147.95–2528.15)646.46 ± 306.26 (91.85–1979.98)0.018Monocyte /red blood cell ratio, mean ± SD, range8.99 ± 2.60 (4.32–15.67)8.42 ± 2.35 (3.63–15.10)0.035Clinical T stage0.001 T111356 T25965Estrogen receptor0.018 Negative5423 Positive11898Progesterone receptor0.039 Negative7035 Positive10286HER20.394 Negative10870 Positive6451Ki670.685 ≤20%6845 >20%10476BMI index0.137 <249959 ≥ 247362Platelet to lymphocyte ratio (PLR)0.004 Low10251 High7070Monocyte to red cell ratio (MRR)0.006 Low8378 High8943Systemic immune-inflammation index(SII)< 0.001 Low9136 High8185HER2: human epidermal growth factor receptor 2; BMI: body mass index; MRR: monocyte to red cells ratio; PLR: platelet to lymphocyte ratio Association between lymph node metastasis and clinicopathological factors HER2: human epidermal growth factor receptor 2; BMI: body mass index; MRR: monocyte to red cells ratio; PLR: platelet to lymphocyte ratio The optimal cut-off values were determined as follows based on receiver operating characteristic (ROC) curve analysis: PLR at 152.48 (sensitivity: 0.579, specificity: 0.593, AUC = 0.584; Fig. 2), SII at 496.92 (sensitivity: 0.702, specificity: 0.529, AUC = 0.581; Fig. 3), and MRR at 8.76 (sensitivity: 0.645, specificity: 0.517, AUC = 0.572; Fig. 4). The AUC values ranging from 0.57 to 0.58 indicate limited discriminatory power, suggesting that these inflammatory markers alone have limited discriminatory capability for ALNM. Fig. 2Receiver operating characteristic (ROC) curve analysis. PLR cut-off value for lymph node metastasis was identified as 152.48. Area under curve was 0.584 (95% CI: 0.517–0.650) with sensitivity 0.579, specificity 0.593 and p = 0.015 Receiver operating characteristic (ROC) curve analysis. PLR cut-off value for lymph node metastasis was identified as 152.48. Area under curve was 0.584 (95% CI: 0.517–0.650) with sensitivity 0.579, specificity 0.593 and p = 0.015 Fig. 3Receiver operating characteristic (ROC) curve analysis. SII cut-off value for lymph node metastasis was identified as 496.92. Area under curve was 0.581 (95% CI: 0.515–0.647) with sensitivity 0.702, specificity 0.529 and p = 0.018 Receiver operating characteristic (ROC) curve analysis. SII cut-off value for lymph node metastasis was identified as 496.92. Area under curve was 0.581 (95% CI: 0.515–0.647) with sensitivity 0.702, specificity 0.529 and p = 0.018 Fig. 4Receiver operating characteristic (ROC) curve analysis. MRR cut-off value for lymph node metastasis was identified as 8.76. Area under curve was 0.572 (95% CI: 0.506–0.638) with sensitivity 0.645, specificity 0.517 and p = 0.035 Receiver operating characteristic (ROC) curve analysis. MRR cut-off value for lymph node metastasis was identified as 8.76. Area under curve was 0.572 (95% CI: 0.506–0.638) with sensitivity 0.645, specificity 0.517 and p = 0.035 No significant age differences were found between ALNM-positive and ALNM-negative groups. However, ALNM was significantly associated with larger tumor size (p < 0.001), higher clinical T stage (p < 0.001), elevated PLR (p = 0.015), increased SII (p = 0.018), and decreased MRR (p = 0.035). Among the 121 ALNM-positive cases, 70 were in the high-PLR group, whereas 102 of the 172 ALNM-negative patients were in the low-PLR group (p = 0.004). Similarly, 78 ALNM-positive patients belonged to the low-MRR group, compared to 89 ALNM-negative patients in the high-MRR group (p = 0.006). Additionally, 85 ALNM-positive patients were classified as having high SII, while 91 ALNM-negative patients were categorized as having low SII (p < 0.001). No significant associations were found between PLR, MRR, or SII and other clinicopathological features (Table 3). Table 3Association between platelet to lymphocyte ratio (PLR), monocyte to red cell ratio (MRR), systemic immune-inflammation index (SII) and clinicopathological factorsVariablesPLRMRRSIILow(153 patients 52.2%)High(140 patients 47.8%)P valueLow(161 patients 54.9%)High(132 patients 45.1%)P valueLow(127 patients 43.3%)High166 patients 56.7%)P valueAge, years, mean ± SD, range56.36 ± 10.15 (33–74)55.24 ± 11.00 (28–78)56.2 ± 9.89 (28–73)55.52 ± 11.47 (33–78)57.47 ± 9.47 (33–77)54.69 ± 11.23(28–78)Tumour size, mm, mean ± SD,2.05 ± 0.98 (0.3–5)2.06 ± 0.93 (0.2–4.5)2.09 ± 0.94 (0.2–5)2.01 ± 0.97 (0.3–5)2.04 ± 1.01 (0.3–5)2.07 ± 0.91 (0.2–5)Clinical T stage0.5150.3590.677 T1917889807594 T2626272525272Estrogen receptor0.4580.250.332 Negative433438393740 Positive1101061239390126Progesterone receptor0.6550.3650.066 Negative535254515352 Positive100881078174114HER20.6230.7750.970 Negative9583997977101 Positive585762535065Ki670.8090.0960.471 ≤20%585569444667 >20%958592888199BMI index0.1270.3250.725 <24768291676791 ≥ 24775870656075Clinical lymph node metastasis 0.004 0.006 <0.001 No1027083899181 yes517078433685HER2: human epidermal growth factor receptor 2; BMI: body mass index; MRR: monocyte to red cell ratio; PLR: platelet to lymphocyte ratio; SII: systemic immune-inflammation indexBold values indicate statistical significance (P < 0.05) Table 3Association between platelet to lymphocyte ratio (PLR), monocyte to red cell ratio (MRR), systemic immune-inflammation index (SII) and clinicopathological factorsVariablesPLRMRRSIILow(153 patients 52.2%)High(140 patients 47.8%)P valueLow(161 patients 54.9%)High(132 patients 45.1%)P valueLow(127 patients 43.3%)High166 patients 56.7%)P valueAge, years, mean ± SD, range56.36 ± 10.15 (33–74)55.24 ± 11.00 (28–78)56.2 ± 9.89 (28–73)55.52 ± 11.47 (33–78)57.47 ± 9.47 (33–77)54.69 ± 11.23(28–78)Tumour size, mm, mean ± SD,2.05 ± 0.98 (0.3–5)2.06 ± 0.93 (0.2–4.5)2.09 ± 0.94 (0.2–5)2.01 ± 0.97 (0.3–5)2.04 ± 1.01 (0.3–5)2.07 ± 0.91 (0.2–5)Clinical T stage0.5150.3590.677 T1917889807594 T2626272525272Estrogen receptor0.4580.250.332 Negative433438393740 Positive1101061239390126Progesterone receptor0.6550.3650.066 Negative535254515352 Positive100881078174114HER20.6230.7750.970 Negative9583997977101 Positive585762535065Ki670.8090.0960.471 ≤20%585569444667 >20%958592888199BMI index0.1270.3250.725 <24768291676791 ≥ 24775870656075Clinical lymph node metastasis 0.004 0.006 <0.001 No1027083899181 yes517078433685HER2: human epidermal growth factor receptor 2; BMI: body mass index; MRR: monocyte to red cell ratio; PLR: platelet to lymphocyte ratio; SII: systemic immune-inflammation indexBold values indicate statistical significance (P < 0.05) Association between platelet to lymphocyte ratio (PLR), monocyte to red cell ratio (MRR), systemic immune-inflammation index (SII) and clinicopathological factors HER2: human epidermal growth factor receptor 2; BMI: body mass index; MRR: monocyte to red cell ratio; PLR: platelet to lymphocyte ratio; SII: systemic immune-inflammation index Bold values indicate statistical significance (P < 0.05) Univariate logistic regression analysis identified elevated PLR (OR = 0.500, 95% CI: 0.312–0.802, p = 0.004), decreased MRR (OR = 1.945, 95% CI: 1.207–3.136, p = 0.006), increased SII (OR = 0.377, 95% CI: 0.231–0.616, p < 0.001), and higher T stage (OR = 0.450, 95% CI: 0.279–0.724, p = 0.001) as significant predictors of ALNM. In the multivariate analysis, patients with a low PLR had a significantly lower risk of ALNM than those with a high PLR (adjusted OR = 0.447, 95% CI: 0.269–0.741, p = 0.002). Similarly, low SII was associated with a lower risk of ALNM compared to high SII (adjusted OR = 0.323, 95% CI: 0.189–0.553, p < 0.001). Conversely, low MRR was associated with a higher risk of ALNM than high MRR (adjusted OR = 1.862, 95% CI: 1.125–3.082, p = 0.016) (Table 4). Multivariate logistic regression confirmed that elevated PLR and SII levels were significantly associated with an increased risk of ALNM. In these models, the ‘High’ level groups (PLR > 152.48, SII > 496.92) served as the reference categories, resulting in ORs < 1 for the corresponding ‘Low’ level groups. Table 4Univariate and multivariate analysis of factors associated with lymph node metastasisParametersUnivariate analysisMultivariate analysisOdds ratio95%CIp-ValueOdd ratio95%CIp-ValueAge at surgery (years old) ≤ 50 vs. >500.7250.442–1.1890.203Clinical T stage T1 vs. T20.4500.279–0.724 0.001 Estrogen receptor Negative vs. positive0.5130.294–0.895 0.019 Progesterone receptor Negative vs. positive0.5930.361–0.975 0.039 HER2 Negative vs. positive0.8130.506–1.3080.394Ki67 ≤ 20% vs. >20%0.9060.561–1.4620.685BMI index ≥ 24 vs. <240.7020.440–1.1200.137Platelet to lymphocyte ratio (PLR) Low vs. High0.5000.312–0.802 0.004 0.4470.269–0.741 0.002 Monocyte to red cell ratio (MRR) Low vs. High1.9451.207–3.136 0.006 1.8621.125–3.082 0.016 Systemic immune-inflammation index(SII) Low vs. High0.3770.231–0.616 <0.001 0.3230.189–0.553 <0.001 The reference category for each inflammatory marker was the ‘High’ group, defined by ROC-derived cut-off values: PLR (> 152.48), MRR (<8.76), and SII (> 496.92). An odds ratio (OR) < 1.0 for the ‘Low’ group indicates a lower risk of ALNM than the ‘High’ reference groupHER2: human epidermal growth factor receptor 2; CI: confidence intervalBold values indicate statistical significance (P < 0.05) Table 4Univariate and multivariate analysis of factors associated with lymph node metastasisParametersUnivariate analysisMultivariate analysisOdds ratio95%CIp-ValueOdd ratio95%CIp-ValueAge at surgery (years old) ≤ 50 vs. >500.7250.442–1.1890.203Clinical T stage T1 vs. T20.4500.279–0.724 0.001 Estrogen receptor Negative vs. positive0.5130.294–0.895 0.019 Progesterone receptor Negative vs. positive0.5930.361–0.975 0.039 HER2 Negative vs. positive0.8130.506–1.3080.394Ki67 ≤ 20% vs. >20%0.9060.561–1.4620.685BMI index ≥ 24 vs. <240.7020.440–1.1200.137Platelet to lymphocyte ratio (PLR) Low vs. High0.5000.312–0.802 0.004 0.4470.269–0.741 0.002 Monocyte to red cell ratio (MRR) Low vs. High1.9451.207–3.136 0.006 1.8621.125–3.082 0.016 Systemic immune-inflammation index(SII) Low vs. High0.3770.231–0.616 <0.001 0.3230.189–0.553 <0.001 The reference category for each inflammatory marker was the ‘High’ group, defined by ROC-derived cut-off values: PLR (> 152.48), MRR (<8.76), and SII (> 496.92). An odds ratio (OR) < 1.0 for the ‘Low’ group indicates a lower risk of ALNM than the ‘High’ reference groupHER2: human epidermal growth factor receptor 2; CI: confidence intervalBold values indicate statistical significance (P < 0.05) Univariate and multivariate analysis of factors associated with lymph node metastasis The reference category for each inflammatory marker was the ‘High’ group, defined by ROC-derived cut-off values: PLR (> 152.48), MRR (<8.76), and SII (> 496.92). An odds ratio (OR) < 1.0 for the ‘Low’ group indicates a lower risk of ALNM than the ‘High’ reference group HER2: human epidermal growth factor receptor 2; CI: confidence interval Bold values indicate statistical significance (P < 0.05) Discussion Axillary lymph node metastasis (ALNM) was pathologically confirmed in approximately 25% of T1–2 breast cancer cases; however, traditional preoperative evaluation tools such as ultrasound and MRI remain limited in terms of sensitivity and specificity [11, 12]. In this cohort of 293 patients with early stage breast cancer, larger tumor size, higher clinical T stage, and increased platelet-to-lymphocyte ratio (PLR) were all significantly associated with lymph node metastasis [13, 14]. No significant association was observed for ER, PR, Ki-67, or HER2 status. These findings are consistent with earlier studies [15–17].Our multivariate analysis confirmed the association. Specifically, patients in the low PLR group exhibited a 55.3% lower risk of ALNM compared to those in the high PLR group (OR = 0.447). A similar protective effect was observed for low SII (OR = 0.323). In contrast, patients in the low MRR group had an 86.2% higher risk of ALNM than those in the high MRR group (OR = 1.862). Our finding that elevated preoperative PLR is independently associated with ALNM is consistent with the results reported by Wang et al. [14], who also identified PLR as a significant biomarker in a similar cohort. Similarly, the association between high SII and LNM aligns with the prognostic role of SII described by Zhou et al. [8]. Recent studies have increasingly focused on the relationship between systemic inflammatory responses and the tumor microenvironment as potential means of assessing metastatic risk [18, 19]. In the present study, we found that higher SII and decreased MRR were independently associated with axillary LNM in early stage breast cancer. These findings are consistent with the proposed role of immune and inflammatory regulation in nodal spread. The SII has previously been established as a prognostic indicator of breast cancer. For instance, Zhu et al. reported that SII independently predicted disease-free survival (DFS) and overall survival (OS) in both neoadjuvant (n = 477) and non-neoadjuvant (n = 308) cohorts [20]. Similarly, Liu et al. showed superior survival outcomes in the low-SII groups across early- and late-stage breast cancer and in those responsive to neoadjuvant chemotherapy [21]. The prognostic power of SII may stem from the pro-metastatic roles of neutrophils: they secrete neutrophil elastase (NE), transferrin, and other mitogens to promote tumor proliferation; release pro-angiogenic factors such as VEGF, MMP-9, and IL-17; and form neutrophil extracellular traps (NETs) that support metastatic colonization [22–24]. In triple-negative breast cancer (TNBC), neutrophil-driven angiogenesis appears to be more pronounced. Circulating tumor cells (CTCs) can bind to neutrophils and platelets, forming aggregates that shield tumor cells from immune surveillance [25]. In addition, platelets express immune checkpoint molecules such as PD-L1, which can dampen T-cell activity, particularly during the early stages of metastatic niche development [26, 27]. To the best of our knowledge, this is the first study to demonstrate a significant and independent association between a decreased peripheral blood MRR and increased risk of ALNM in breast cancer. A possible explanation lies in the role of monocytes in the tumor microenvironment. Monocytes can differentiate into tumor-associated macrophages (TAMs), which promote invasion and metastasis through the secretion of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and subsequent extracellular matrix remodeling [28]. In TNBC, TAMs further influence the ECM via S100A8/A9 proteins, thereby enhancing metastatic efficiency [29]. A reduction in circulating monocytes may impair their differentiation into classically activated M1 macrophages, weakening antitumor immune activity. Additionally, the changes in cytokine profile—characterized by lower levels of IL-12 and IFN-γ and increased expression of IL-6 and TNF-α—may further favor an immunosuppressive milieu [30, 31]. Such shifts contribute to T cell dysfunction and the expansion of regulatory T cells. Alterations in erythrocyte parameters may also reflect cancer-related anemia and disrupted hematopoiesis. Together, these findings suggest that fluctuations in MRR may mirror immune and microenvironmental alterations associated with metastatic progression. The observed negative association between MRR and ALNM risk may reflect complex immune regulation in breast cancer progression. However, given the exploratory nature of this finding and the limited discriminatory ability of MRR, these biological interpretations should be considered preliminary and require validation in future studies. Although our study focused on systemic hematological markers, recent molecular investigations provide converging evidence on the critical role of the immune microenvironment in breast cancer metastasis. For instance, recent studies have identified specific immune regulators such as CLIC6 and CORO1A as pivotal factors influence tumor progression and patient prognosis [32, 33]. These findings, while operating at the cellular and genetic levels, corroborate our observation that immune balance—reflected systemically by indices such as SII and MRR—is fundamentally linked to the metastatic potential of breast cancer. This multi-level evidence underscores the importance of immune surveillance mechanisms in determining axillary lymph node involvement. This was a hypothesis-generating retrospective study. The biological explanations provided for the observed associations are exploratory and should be tested in prospective, mechanistic studies before definitive definitive conclusions about causal relationships. This study has several limitations. First, its retrospective nature introduces potential selection bias and limits causal inference. Second, the single-center design may affect the generalizability of our findings.Third, the lack of external validation cohort limits the robustness of our identified cut-off values. Fourth, we assessed inflammatory markers at a single time point, without evaluating their dynamic changes during disease progression. Fifth, although we implemented strict exclusion criteria to minimize confounding by active infections, hematological disorders, and recent transfusions, the inherent limitations of a retrospective design prevent us from fully accounting for all potential confounders. Specifically, we were unable to systematically screen for or exclude patients with subclinical infections, undiagnosed chronic inflammatory conditions (e.g., periodontitis, asymptomatic autoimmune activity), or other physiological stressors that can subtly but significantly elevate systemic inflammatory markers like PLR and SII, or alter MRR. These unmeasured factors may have introduced residual confounding into our analysis, potentially biasing the observed associations. To definitively establish the predictive value of these markers, future prospective studies should incorporate more rigorous pre-enrollment screening protocols, such as routine testing for C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and detailed patient interviews to rule out any sources of non-malignant inflammation. Future prospective, multi-center studies with larger cohorts and external validation are warranted to confirm these findings. Additionally, investigating the temporal dynamics of these markers and their integration into comprehensive predictive models would enhance their clinical utility. Peripheral blood parameters can also be affected by factors unrelated to the tumor, including infection and chronic inflammatory conditions. Strict criteria for patient selection and standardized timing of blood collection would help reduce variability in future studies. Although the present analysis supports an association between systemic inflammatory markers and nodal metastasis, the underlying biological mechanisms require further clarification. Pathways linking inflammatory indices to processes such as epithelial–mesenchymal transition and bone marrow–derived immune cell dynamics merit additional investigation. We did not conduct detailed subgroup analyses according to molecular subtype. However, SII, PLR, and MRR remained significantly associated with lymph node metastasis in multivariate models, and their AUC values in the overall cohort were acceptable. These findings suggest that these markers may be valuable broadly applicable, preoperative indicators, particularly in settings where detailed pathological stratification is not available. Future studies should examine their performance within specific molecular subtypes to better define their clinical role. Advanced approaches, including single-cell RNA sequencing and spatial transcriptomic analysis, may provide further insight into the biological basis of these associations. Conclusion Although preoperative SII, PLR, and MRR show statistically significant associations with ALNM, their limited discriminatory ability (AUCs ranging from 0.57 to 0.58) suggests they should be considered as adjunctive or supportive indicators rather than definitive predictors. These markers may contribute to a comprehensive risk assessment model when combined with established clinicopathological factors. Further work should explore combining hematologic indices with imaging-based features and molecular classification to improve predictive accuracy. The integration of blood-based markers with radiologic and genomic data may help develop more comprehensive risk models and support more individualized management strategies in breast cancer. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1.